The companies developing Ebvallo reached an agreement with the FDA to address its main reason for rejecting the drug.
Dive deeper with STAT+. Gain unlimited access to expert analysis, newsletters, events, and news alerts.
In this week's Biotech Scorecard newsletter, Adam Feuerstein takes on the company touting gold microdust suspended in water ...
A Cytokinetics heart disease drug — already approved in one indication — succeeded in another Phase 3 trial, a potential boost for sales.
The runup to next month’s annual meeting of the American Society of Clinical Oncology has started, and a good bit of the Wall ...
The drugmaker Erasca said results on its experimental pill in a trial of pancreatic cancer and non-small cell lung cancer ...
A long-acting injectable treatment for plaque psoriasis helped 63% of patients achieve complete skin clearance in a clinical ...
Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast ...
Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast ...
Adam Feuerstein, a senior writer and biotech columnist, is the author of Adam’s Biotech Scorecard, a subscriber-only newsletter about the crossroads of drug development, business, Wall Street, and ...
Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results